- Home
- CHRS vs KFS Comparison
CHRS vs KFS Comparison
Compare CHRS & KFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHRS | KFS |
|---|---|---|
| Founded | 2010 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.8M | 325.8M |
| IPO Year | 2014 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CHRS | KFS |
|---|---|---|
| Price | $1.66 | $10.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.51 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 54.2K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 472.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $134,996,000.00 |
| Revenue This Year | $73.08 | N/A |
| Revenue Next Year | $30.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.42 |
| 52 Week Low | $0.72 | $9.84 |
| 52 Week High | $2.62 | $16.80 |
Technical Indicators
Market Signals| Indicator | CHRS | KFS |
|---|---|---|
| Relative Strength Index (RSI) | 42.56 | 45.34 |
| Support Level | $1.55 | $10.00 |
| Resistance Level | $1.80 | $12.07 |
| Average True Range (ATR) | 0.11 | 0.53 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 6.93 | 38.10 |
Price Performance
Historical ComparisonAbout CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The company generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.